Tasquinimod - Active Biotech
Alternative Names: ABR-215050; TASQLatest Information Update: 30 Sep 2024
At a glance
- Originator Active Biotech
- Developer Active Biotech; Ipsen; University of Pennsylvania
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Phase II Myelofibrosis
- Phase I/II Multiple myeloma
- Preclinical Myelodysplastic syndromes
- Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer
Most Recent Events
- 20 Sep 2024 Active Biotech plans a phase I/II TasqForce trial for Myelofibrosis (Second-line therapy or greater) in Germany and in the Netherlands in October 2024 (NCT06605586)
- 30 Aug 2024 Active Biotech plans a phase II proof-of-concept trial for Myelofibrosis in USA in mid 2024 (NCT06327100)
- 01 Aug 2024 Phase-II clinical trials in Myelofibrosis (Combination therapy) in USA (PO) (NCT06327100)